Background and purpose: There is debate as to whether the apparent rebound after fingolimod discontinuation is related to the discontinuation itself or whether it is due to the natural course of highly active multiple sclerosis (MS). Our aim was to survey the prevalence of severe reactivation and rebound after discontinuation of fingolimod in a cohort of Italian patients with MS. Methods: Patients with relapsing-remitting MS who were treated with fingolimod for at least 6 months and who stopped treatment for reasons that were unrelated to inefficacy were included in the analysis. Results: A total of 100 patients who had discontinued fingolimod were included in the study. Fourteen patients (14%) had a relapse within 3 months after fingolimod discontinuation, and an additional 12 (12%) had a relapse within 6 months. According to this study's criteria, 10 patients (10%) had a severe reactivation. Amongst these patients, five (5%) had a reactivation that was considered to be a rebound. Conclusions: The present study showed that more than 26% of patients are at risk of having a relapse within 6 months after fingolimod discontinuation. Nevertheless, the risk of severe reactivations and rebound is lower than has been previously described.
Introduction
Fingolimod was the first oral treatment to become available for multiple sclerosis (MS). In Europe, its use is indicated for aggressive forms of relapsingremitting MS. Data from clinical trials showed that annualized relapse rates (ARRs) were more than 50% lower in subjects taking oral fingolimod compared to subjects taking placebo [1, 2] . Since 2012, several reports have described a 'rebound syndrome' after fingolimod discontinuation [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . There is no shared definition of 'clinical rebound syndrome'; the most widely used definition is 'a disease reactivation which surpasses the pretreatment activity level', especially with regard to ARR [15, 16] . The concept of 'rebound' after discontinuation of treatment was first proposed for natalizumab, a monoclonal antibody approved in 2006 to treat the aggressive course of MS [17] . To date, only one study has explored the frequency of this phenomenon in patients with MS who discontinued fingolimod use. In this study, a clinical rebound syndrome was detected in five out of 46 subjects of a small cohort of patients who were referred to a single site (10.9%) [18] . However, a recent post hoc analysis of the phase III placebo-controlled FREEDOMS and FREEDOMS II trials did not find any difference in the emergence of clinical rebound between patients treated with fingolimod and placebo [16] . To note, the minimum time of exposure of the patients evaluated in that post hoc analysis was 3 months, and such a short exposure may be less likely to cause a rebound. In addition, the FREE-DOMS trials collected magnetic resonance imaging (MRI) data post-fingolimod discontinuation only for 3 months, and the subjects included in the rebound analysis are a small fraction of those enrolled.
Whilst there is agreement in the literature that there is a high risk of rebound after natalizumab discontinuation [17] , the concept of rebound after fingolimod cessation is less well defined.
The aim of this multicenter study was to evaluate the presence of clinical rebound syndrome after fingolimod discontinuation in a cohort of Italian patients with MS.
Materials and methods
The patients who were enrolled in this study were recruited from 14 Italian MS centers between March and October 2017, after signed informed consent. The study was approved by the local ethics committees. The inclusion criteria were as follows: diagnosis of relapsing-remitting MS according to the McDonald criteria, previous treatment with fingolimod for at least six consecutive months over the person's lifetime, an absence of relapses in the last 6 months of treatment with fingolimod, and suspension of fingolimod due to reasons other than inefficacy (i.e. desire to become pregnant, side effects, self-discontinuation). Following the Italian Medicines Agency (AIFA) rules, all subjects started fingolimod due to aggressive disease from the onset (na€ ıve patients), inefficacy of firstline treatments (switching patients) or a high risk of progressive multifocal leukoencephalopathy during natalizumab therapy. At each center from which patients were recruited, a neurologist with expertise in MS diagnosis and treatment collected the following demographic and clinical information from the patients' data records: gender; year of birth; age at onset; comorbidities; the last disease-modifying drug (DMD) before fingolimod and the first DMD after its discontinuation; reason for suspension of fingolimod; ARR before, during and after fingolimod; and Expanded Disability Status Scale (EDSS) score at the time that fingolimod was started and stopped, as well as during the post-suspension relapses.
A severe reactivation was defined as a relapse with an associated EDSS increase of at least 2 points or as two or more relapses in the 6 months following fingolimod discontinuation. A rebound was defined when such a high clinically severe reactivation, as previously described, was never reported in the patient's lifetime before fingolimod discontinuation. Thus, if the patient experienced the same severe disease activity both after fingolimod cessation and before (in any period of the course of the disease), that reactivation was not considered a rebound.
Statistical analysis
Quantitative results are presented as mean and standard deviation (SD) or median with the interquartile range (IQR). Absolute counts and percentages are reported for counts and binary variables. To evaluate demographic and clinical features as possible prognostic factors for severe reactivation after discontinuation of fingolimod, comparisons between patients with and without a severe reactivation were made using an independent samples Student's t test (age at first dose of fingolimod), a non-parametric Mann-Whitney U test (disease duration at first dose of fingolimod, duration of fingolimod treatment, EDSS score at fingolimod discontinuation and ARR in the year before fingolimod initiation) and a chisquared test (gender and comorbidities). A P value <0.05 was considered statistically significant. Statistical analyses were performed with Stata (v.14; StataCorp, College Station, TX, USA) software.
Results
A total of 100 patients, 80 female (80%) and 20 male (20%), were included in the study. The mean age at onset was 27 years (SD 8.7). At the time that fingolimod was started, the median EDSS and the mean duration of the disease were 2 (IQR 1.5-3.5) and 10.7 (SD 6.8), respectively. The median EDSS at the end of the treatment was 2 (IQR 1-3.5). The mean duration of fingolimod treatment was 1.9 years (SD 1.5, range 0.5-5.9).
The vast majority of patients (70, 69.3%) started fingolimod therapy due to inefficacy of the first-line treatment, whereas 26 (25.75%) switched from natalizumab due to the high risk of progressive multifocal leukoencephalopathy and five (4.95%) had an aggressive course of the disease and were na€ ıve to DMDs. The reasons for discontinuation of fingolimod were side effects or adverse events in 57 patients (57%), the desire to become pregnant in 33 patients (33%) and the patient's choice in 10 patients (10%).
After fingolimod, a new DMD was started in 72 patients within a median time of 3 months (IQR 1.1-6.1). Sixty subjects did not experience any relapse after fingolimod discontinuation during the whole follow-up. Of them, 40 started a new DMD after a mean time of 5 months (IQR 0.9-4.8). The ARR before, during and after fingolimod regarding the whole cohort of patients is shown in Fig. 1 .
Forty subjects had a relapse during the follow-up. In particular, 14 out of 100 patients (14%) had a relapse within 3 months after fingolimod discontinuation (only one started a new therapy within 3 months from the time that fingolimod was discontinued), and an additional 12 patients (12%) had a relapse within 6 months (five started a new therapy within 6 months from the time that fingolimod was discontinued). According to the above-mentioned criteria, 10 patients (10%) had a clinically severe reactivation. Amongst them, one had a relapse associated with an EDSS increase of 6 points, two had a relapse associated with an EDSS increase of 3.5 points, two had a relapse associated with an EDSS increase of 2 points, and five had at least two relapses over 6 months. Upon analysis of the patients with severe reactivation, five of them (5% of the whole cohort) were defined as having had a clinical rebound. The demographic and clinical features of patients who experienced severe reactivation and rebound of the disease after discontinuation of fingolimod are reported in Table 1 .
From the analysis of clinical and demographic features, it was not possible to detect significant prognostic factors for severe reactivation of disease. However, patients with a severe reactivation were younger and all were female. The detailed results are presented in Table 2 .
The details about EDSS course, new and enhancing lesions on the brain MRI, and features of clinical reactivation are reported in Table 3 .
Discussion
A retrospective, observational, real-life study was conducted involving a cohort of MS patients who were treated with fingolimod and who discontinued therapy for reasons other than poor efficacy. According to AIFA directions, when fingolimod was started all of the patients had an aggressive disease course, defined either as at least one relapse during interferon beta or glatiramer acetate treatment or at least two relapses in the last year if the patient was not taking a DMD. Moreover, the patients' disease was stable during treatment, and the treatment was discontinued for side effects, the desire to become pregnant or reasons other than inefficacy. In our cohort, 10% of patients experienced a severe reactivation of MS, and the reactivations of half of these patients met the definition of clinical rebound syndrome. As proposed in the recent analysis of the FREEDOMS and FREEDOMS II trials [16] , patients experiencing a severe reactivation after discontinuation of fingolimod may simply have had a high level of MS activity, compared to their pre-fingolimod clinical histories, which would be expected as part of the natural, unpredictable course of the disease.
It is worth noting that some of the clinical case studies that have described a rebound after fingolimod discontinuation [6] [7] [8] [9] 13] , including the small cohort that was described by Hatcher et al. [18] , studied patients in whom fingolimod was discontinued due to a lack of efficacy. Given that these patients did not Figure 1 Representation of the annualized relapse rate (ARR) before, during and after fingolimod in three groups of patients: those without relapses after fingolimod discontinuation, those who experienced reactivation and those who experienced a rebound of the disease. FTY, fingolimod. [Colour figure can be viewed at wileyonlinelibrary.com] respond to fingolimod, a reactivation of the disease would be expected upon therapy discontinuation. Recently, a high relapse rate and a low EDSS score before fingolimod treatment have been hypothesized to be negative prognostic factors for severe disease reactivation within the first 3 months after cessation of the therapy [19] . In our study, it was not possible to identify factors that were strongly associated with severe reactivation after discontinuation of fingolimod. It is important to note, however, that all the patients with severe reactivation were female and were also younger than the other subjects, despite the fact that these differences did not reach statistical significance. This may have been due to the low statistical power of these comparisons.
Currently, there is no agreement on the pathological explanation for the supposed rebound. It is possible that it is related to a rapid lymphocyte reconstitution [18] , but such a reconstitution has not been observed in all patients with a rebound. A more likely hypothesis is that a differential lymphocyte subset repopulation may be driving the rebound syndrome [20] . Moreover, it has been shown in the experimental model of MS that rebound after fingolimod discontinuation is preceded by an overexpression of sphingosine 1 phosphate receptor 1 (S1P1) in lymphocytes entrapped in lymph nodes, and it correlates with their massive egress from lymph nodes and with infiltrates in the central nervous system [21] .
One important limitation of this study is that rebound was considered only on the basis of clinical, but not radiological, features. This is due to the observational and retrospective design of this study, in which data collected in clinical practice were analyzed. MRI examinations were not homogeneously performed across centers, both in terms of imaging protocols and in terms of timing of the scanning, and only a few patients underwent an MRI examination within the first 6 months after fingolimod discontinuation. Of note, clinical and radiological rebounds were considered as two separate entities in the analysis of the FREEDOMS and FREEDOMS II studies [16] . Another limitation, due to the fact that it is a real-life study, is the lack of lymphocyte subset after fingolimod discontinuation for the vast majority of patients. That being said, the cohort of patients included in this study was selected from specialized Italian MS centers that belong to the research group i-MuST. Given their participation in iMUST, these centers share relatively homogeneous rules for MS treatment and for strict observation of AIFA rules. In accordance with these prescriptive rules, only patients who fail a first-line treatment and those with an aggressive course of MS from the onset of the disease could take fingolimod. AE, adverse event; Alem, alemtuzumab; DMD, disease-modifying drug; EDSS, Expanded Disability Status Scale; fingo, fingolimod; GA, glatiramer acetate; IFN, interferon beta; MRI, magnetic resonance imaging; Nat, natalizumab; Pt, patient; Ritux, rituximab; Terifl, teriflunomide.
Thus, all the patients had an aggressive course before the fingolimod initiation.
In conclusion, the rate of rebound after fingolimod discontinuation was estimated to be 5% in this relatively large case series, which is a lower risk than that which was previously described in another real-life cohort [18] . These data could have an important impact in the physician-patient communication, both when fingolimod is proposed as new therapy and when it has to be stopped for any reason. Moreover, even if the risk emerging from our study is not as high as previously described, it has to be considered every time fingolimod is discontinued. To confirm our results, it could be important to conduct other real-life studies analyzing the impact of clinical, and possibly radiological, rebound after fingolimod cessation in relapsing-remitting MS patients without disease activity before the discontinuation.
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